Thermo Fisher Scientific Stock Buy or Sell? TMO Stocks Forecast

Market Capitalization: 211 785 957 000 $
EBITDA: 10 796 000 000 $
Price to Earnings: 35.46
Quarterly Earnings Growth YOY: 0.054
Quarterly Revenue Growth YOY: -0.049
Trailing PE: 35.46
Forward PE: 25.32
Shares Outstanding: 386372000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Thermo Fisher Scientific Stock Buy or Sell? TMO Stocks Analytic Forecasts

Updated on February 24, 2024 (09:16)

Thermo Fisher Scientific Inc. (TMO prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the TMO stock market. Experts share their opinions on what to expect from the Thermo Fisher Scientific Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Thermo Fisher Scientific stocks.

Thermo Fisher Scientific Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy TMO Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Leo Nelissen and is titled

“Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness”

is published on February 6 (2024) and has 1 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today’s company focuses on that.
  • Thermo Fisher Scientific Inc. just reported strong Q4 earnings, with adjusted EPS exceeding expectations and a margin increase from the previous year.
  • Thermo Fisher Scientific’s growth strategy focuses on high-impact innovation, trusted partner status, and an unparalleled commercial engine.

The author starts his analytic review with the following:

Introduction I just wrote an article on one of my favorite healthcare stocks, drug manufacturer AbbVie (ABBV). Like many of its peers, the stock has been through elevated uncertainty regarding the loss of a major patent.

This author is very popular among the auditory. He has 29985 followers

Leo Nelissen is the contributor of experts community since 2015 and has a great number of published articles – 2532.


One more noteworthy article is written by Investor Aide under the title

“Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics”

on January 16 (2024) and has 2 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add TMO stocks to your investment portfolio or not, and helps to work out your own Thermo Fisher Scientific stock selling strategies:

  • Thermo Fisher Scientific reported $44.98 billion revenue in 2022 with a breakup of 29% for life science solutions and 47% for laboratory products and biopharma services among others.
  • These revenue figures were 15% higher than the previous year, and almost a 50% rise in a five-year span.
  • The company may be considered a blue chip one, but still shows a lot of signs of being a growth stock.
  • For investors with a short-term horizon, it may be overvalued. However, it appears well priced for long term investors and even those with medium-term investment strategies.

Investor Aide starts analysis with such words:

Thermo Fisher Scientific Inc. (NYSE:TMO) is a supplier of scientific equipment, reagents and software worldwide. It is based in Waltham, Massachusetts and formed through the merging of Thermo Electron and Fisher Scientific in 2006. Throughout the years, Thermo Fisher Scientific has ventured on to acquiring other similar service providers such as Life Technologies Corporation, Alfa Aesar, Affymetrix, PPD and many more.

The author declares an interesting position, and the number of his followers is 160 and it grows, but not that weighty compared to other authors.
Investor Aide has 39 works published.
The contributor of experts community since 2013. Has published at least 39 articles.


Another analysis presented by Lighting Rock Research came out on January 6 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for TMO stocks. It sounds like

“Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With ‘Hold’”

Article has got 0 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Thermo Fisher Scientific Inc., the expert says the following:

  • Thermo Fisher Scientific revises full-year revenue guidance due to sluggish growth in China and diminishing COVID-related revenue.
  • The company has experienced solid organic growth driven by the pharmaceutical and biotech industry, new product launches, and the impact of the global pandemic.
  • Acquisitions have been a significant driver of growth for Thermo Fisher, with successful integration and expansion of their global portfolio.

And here, what comes first:

Thermo Fisher Scientific (NYSE:TMO) has revised their full-year revenue guidance, attributing the adjustment to a 1% core organic growth, primarily influenced by sluggish growth in China and the diminishing impact of COVID-related revenue. Their outlook for FY24’s core organic revenue growth mirrors the levels seen in FY23, indicating another year of modest expansion. In light of these factors, I am initiating coverage with a ‘Hold’ rating and assigning a fair value of $510 per share.

The author declares an interesting position, and the number of his followers is 491 and it grows, but not that weighty compared to other authors.
Lighting Rock Research has 82 analytic reviews published.
The contributor of experts community since 2023


The Share Price of Thermo Fisher Scientific Inc. (TMO) for now

What analysts predict: $595.32
52-week high/low: $591.97 / $415.32

50/200 Day Moving Average: $537.19 / $518.01

The average stock price over the previous 50/200 days. For Thermo Fisher Scientific stocks, the 50-day moving average is the resistance level for now. For TMO stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for TMO stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.